Rheumatology & Immunology Infusion
Centers providing biologic infusions for rheumatoid arthritis, lupus, and autoimmune conditions.
Market snapshot
These figures describe Outpatient Infusion Centers (4.10.18), the segment that Rheumatology & Immunology Infusion sits within. They are not figures for Rheumatology & Immunology Infusion on its own.
- Market size
- ~$70B
- Growth
- ~5.4%CAGR (2017–22, nominal)
- Companies
- ~10,809 firms
Mapped to a broad 'all other outpatient care centers' code, so ~$70B / ~10,800 firms captures more than infusion alone. Still, the site-of-care shift out of the hospital and specialty/biologic drug growth make freestanding infusion the fast-growing core (~5.4%/yr), and it is an active consolidation theme (Option Care, PE-backed platforms).
NAICS 621498. U.S. Census Bureau, 2022 Statistics of U.S. Businesses; U.S. Census Bureau, 2022 Economic Census. A broad residual code that captures other outpatient care beyond infusion centers.
Business model & economics
Revenue model
Drug margin plus infusion-service reimbursement
Key economics
- Recurring revenue
- High
- EBITDA margin
- Drug-margin- and site-of-care-driven
- Capex intensity
- Moderate
recurring chronic infusion
Characteristics
- Site-of-care shift to lower-cost freestanding infusion.
- Biologics and specialty infusibles drive growth.
- Often an ancillary attached to specialty practices.
M&A deal context
Who’s acquiring
- Infusion & specialty-care platforms
- Specialty MSO acquirers
- PE-backed consolidators
What’s driving deals
- Site-of-care shift to lower-cost infusion.
- Biologics and specialty-drug growth.
- Ancillary-driven specialty-practice consolidation.
Find Rheumatology & Immunology Infusion acquisition targets
Search Acquisera’s index for companies classified under Rheumatology & Immunology Infusion (4.10.18.5) and build a targeted deal pipeline.
Search companies